Skip to main content
News and Events banner photo

News & Events
Stay Informed with Industry Insights and Follow Our Progress

Scientist in background holding filled vial in foreground

Filter

Company NewsHomepage NewsNews HighlightRAG-17Uncategorized

Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS

Nantong, China – January 13, 2026 – Ractigen Therapeutics is pleased to announce that the…
January 13, 2026
Company NewsHomepage NewsPresentations

RAG-17, a Novel siRNA Therapy for SOD1-ALS: Safety and Preliminary Efficacy from a First-in-human Trial (Abstract)

Event: American Academy of Neurology (AAN) 2025 Annual Meeting (San Diego) View Abstract View News:…
April 9, 2025
Company NewsHomepage NewsNews HighlightRAG-01

Ractigen’s RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data Presented at EAU 2025

NANTONG, China, and MELBOURNE, Australia, March 24, 2025 – Ractigen Therapeutics, a clinical-stage biopharmaceutical company…
March 24, 2025
Company NewsHomepage NewsNews Highlight

Ractigen Therapeutics Founder Dr. Long-Cheng Li Awarded 2024 Life Science Ice Breaking Award

NANTONG and SUZHOU, China, Dec. 30, 2024 — Ractigen Therapeutics proudly announces that its Founder…
December 31, 2024
Company News

Ractigen Therapeutics Announces First Patient Dosed in Phase I Clinical Trial for RAG-17 in SOD1-ALS

NANTONG and SUZHOU, China, Dec. 24, 2024 — Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated…
December 24, 2024
Company News

Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS

NANTONG and SUZHOU, China, Nov. 19, 2024 — Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated…
November 19, 2024
Close Menu